Toward a common interpretation of the 3Rs principles in animal research
Lab Anim (NY). 2024 Dec;53(12):347-350. doi: 10.1038/s41684-024-01476-2.
PMID:
Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2
Vaccine. 2025 Jan 1;43(Pt 1):126484. doi: 10.1016/j.vaccine.2024.126484. Epub 2024 Nov 8.
PMID:
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Cell Rep. 2024 Nov 26;43(11):114922. doi: 10.1016/j.celrep.2024.114922. Epub 2024 Nov 5.
PMID:
Pre-existing H1N1 immunity reduces severe disease with bovine H5N1 influenza virus
bioRxiv [Preprint]. 2024 Oct 23:2024.10.23.619881. doi: 10.1101/2024.10.23.619881.
PMID:
EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis
Mycoses. 2024 Oct;67(10):e13810. doi: 10.1111/myc.13810.
PMID:
Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria
Vaccines (Basel). 2024 Oct 11;12(10):1156. doi: 10.3390/vaccines12101156.
PMID:
Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic”
Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314.
PMID:
Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity
Open Forum Infect Dis. 2024 Sep 19;11(10):ofae547. doi: 10.1093/ofid/ofae547. eCollection 2024 Oct.
PMID:
mRNA vaccines for infectious diseases – advances, challenges and opportunities
Nat Rev Drug Discov. 2024 Nov;23(11):838-861. doi: 10.1038/s41573-024-01042-y. Epub 2024 Oct 4.
PMID:
Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs
Vaccines (Basel). 2024 Sep 18;12(9):1068. doi: 10.3390/vaccines12091068.
PMID: